Drug Trial Radar · NCT05329766
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
332
Actual
Start
Jun 10, 2022
Primary completion
Sep 7, 2026
Study completion Sep 7, 2026
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- Apr 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Conditions
- Gastrointestinal Tract Malignancies
Interventions
DomvanalimabDrug
Administered as specified in the treatment arm
QuemliclustatDrug
Administered as specified in the treatment arm
ZimberelimabDrug
Administered as specified in the treatment arm
FluorouracilDrug
Administered as specified in the treatment arm
LeucovorinDrug
Administered as specified in the treatment arm
OxaliplatinDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to 18 months
- Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 18 months
Locations
43 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Los Angeles, California
Research Site
Santa Monica, California
Research Site
Derby, Connecticut
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
St. Petersburg, Florida
Research Site
Boston, Massachusetts
Research Site
New York, New York
Research Site
New York, New York
Research Site
Durham, North Carolina
Research Site
Columbus, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Portland, Oregon
Research Site
Nashville, Tennessee
Research Site
Nashville, Tennessee
Research Site
Fairfax, Virginia
Research Site
Toronto, Canada
Research Site
Las Condes, Chile
Research Site
Recoleta, Chile
Research Site
Santiago, Chile
Research Site
Talca, Chile
Research Site
Bordeaux, France
Research Site
Brest, France
Research Site
Caen, France
Research Site
Lille, France
Research Site
Lyon, France
Research Site
Marseille, France
Research Site
Montpellier, France
Research Site
Plérin, France
Research Site
Poitiers, France
Research Site
Rouen, France
Research Site
Toulouse, France
Research Site
Villejuif, France
Research Site
Belgrade, Serbia
Research Site
Kamenitz, Serbia
Research Site
Kragujevac, Serbia
Research Site
Busan, South Korea
Research Site
Daegu, South Korea
Research Site
Hwasun, South Korea
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.